Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenqi Pollen is a Traditional Chinese Medicine (TCM) formulation developed by Xin Qiao Hospital of the Third Military Medical University (Army Medical University) for the treatment of plateau take-off syndrome (high-altitude de-adaptation syndrome). The formulation typically consists of *Ginseng* (Ren Shen), *Astragalus* (Huang Qi), and bee pollen (often from *Brassica campestris*). It is designed to help the body adapt when returning to low altitudes after a long stay at high altitudes, addressing symptoms like fatigue, dizziness, and insomnia. The drug is administered orally in tablet form and has been evaluated in multicenter, double-blind, placebo-controlled clinical trials to assess its efficacy and safety in regulating the body's adaptation mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shenqi Pollen.